Remdesivir significantly cuts hospitalization, death risk in moderate to severe COVID-19 patients: Study
USA: Researchers have found in a randomized, double-blind, placebo-controlled trial involving nonhospitalized patients with COVID-19 that a 3-day course of remdesivir resulted in an 87% lower risk of hospitalization or death than a placebo. The study has been published in the New England Journal of Medicine.
Remdesivir is a direct-acting nucleotide prodrug inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase and it improves clinical outcomes in patients hospitalized with moderate-to-severe Covid-19 infection. Can remdesivir be used in symptomatic, nonhospitalized patients with Covid-19 who are at high risk for disease progression prevent hospitalization is uncertain. To find the same, Robert L. Gottlieb, and the team conducted this study.
The researchers engaged Covid-19 patients who had symptom onset within the previous 7 days and who had at least one risk factor for disease progression (age ≥60 years, obesity, or certain coexisting medical conditions) in the study. They were randomly assigned to receive intravenous remdesivir (200 mg on day 1 and 100 mg on days 2 and 3) or a placebo.
In the study, a total of 562 patients who underwent randomization and received at least one dose of remdesivir or placebo were included in the analyses: 279 patients in the remdesivir group and 283 in the placebo group. The mean age was 50 years, 47.9% of the patients were women, and 41.8% were Hispanic or Latinx. The most common coexisting conditions were diabetes mellitus (61.6%), obesity (55.2%), and hypertension (47.7%).
The primary efficacy endpoint was a composite of Covid-19–related hospitalization or death from any cause by day 28. The primary safety endpoint was any adverse event. A secondary endpoint was a composite of a Covid-19–related medically attended visit or death from any cause by day 28.
It was found that Covid-19–related hospitalization or death from any cause occurred in 2 patients (0.7%) in the remdesivir group and in 15 (5.3%) in the placebo group. Further, a total of 4 of 246 patients (1.6%) in the remdesivir group and 21 of 252 (8.3%) in the placebo group had a Covid-19–related medically attended a visit by day 28. No patients had died by day 28. Adverse events occurred in 42.3% of the patients in the remdesivir group and in 46.3% of those in the placebo group.
The researchers concluded that among nonhospitalized patients who were at high risk for Covid-19 progression, a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of hospitalization or death than placebo.
For further reference log on to:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.